Erick Wayne DeVinney - 16 Mar 2026 Form 4 Insider Report for Axogen, Inc. (AXGN)

Role: Chief Innovation Officer
Signature: /s/ Marc Began, as attorney-in-fact for Erick DeVinney
Issuer symbol: AXGN
Transactions as of: 16 Mar 2026
Net transactions value: -$171,458
Form type: 4
Filing time: 18 Mar 2026, 16:11:17 UTC
Previous filing: 02 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
DeVinney Erick Wayne	Chief Innovation Officer	13631 PROGRESS BLVD.,, SUITE 400, ALACHUA	/s/ Marc Began, as attorney-in-fact for Erick DeVinney	18 Mar 2026	0001595972

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AXGN	Common Stock	Options Exercise		+6,363	+2.5%	$0.000000^*	259,297	16 Mar 2026	Direct	F1
transaction	AXGN	Common Stock	Tax liability		-2,870	-1.1%	$32.84^*	256,427	16 Mar 2026	Direct	F2
transaction	AXGN	Common Stock	Options Exercise		+11,575	+4.5%	$0.000000^*	268,002	16 Mar 2026	Direct	F1
transaction	AXGN	Common Stock	Sale	$171,458	-5,221	-1.9%	$32.84	262,781	16 Mar 2026	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AXGN	Restricted Stock Units	Options Exercise		+6,363		$0.000000^*	6,363	16 Mar 2026	Common Stock	6,363		Direct	F3, F4
transaction	AXGN	Restricted Stock Units	Options Exercise		+11,575		$0.000000^*	11,575	16 Mar 2026	Common Stock	11,575		Direct	F3, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026.
F2	This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale.
F3	Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F4	All shares of Axogen Inc. common stock underlying the restricted stock units are fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vested each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting dates.
F5	All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date.